Automatic EMG-guided botulinum toxin treatment of spasticity
Conventional electromyographic (EMG) guidance in botulinum toxin therapy can localize a muscle, but the amount of electrical activity is assessed only subjectively. We wanted to introduce a quantitative EMG criterion, according to which the decision for/against toxin application could be made. Turn/...
Gespeichert in:
Veröffentlicht in: | Clinical neuropharmacology 1997-06, Vol.20 (3), p.195-203 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 203 |
---|---|
container_issue | 3 |
container_start_page | 195 |
container_title | Clinical neuropharmacology |
container_volume | 20 |
creator | FINSTERER, J FUCHS, I MAMOLI, B |
description | Conventional electromyographic (EMG) guidance in botulinum toxin therapy can localize a muscle, but the amount of electrical activity is assessed only subjectively. We wanted to introduce a quantitative EMG criterion, according to which the decision for/against toxin application could be made. Turn/amplitude analysis (TAA) was applied to nine patients with severe paraspasticity (n = 5), right upper or lower limb spasticity (n = 3), or tetraspasticity (n = 1) before and after toxin administration. Muscles were selected for toxin application if both mean turns/second and mean amplitude/turn exceeded the level of 150. A mean Dysport dose of 116 mouse units (mu) (range 40-240 mu) was administered to each of the 26 muscles that met the EMG criterion. Thirty days after the injection, activities of daily living, pain, and TAA count improved in 89%, tone in 78%, and range of motion in 56% of the patients by at least 1 point on corresponding 5-point rating scales. TAA provides a useful EMG criterion for/against botulinum toxin application. Muscle selection according to this criterion leads to a significant subjective and objective toxin effect. TAA is a valuable tool to determine the benefit of single and subsequent botulinum toxin injections in the treatment of spasticity. |
doi_str_mv | 10.1097/00002826-199706000-00002 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1097_00002826_199706000_00002</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9197941</sourcerecordid><originalsourceid>FETCH-LOGICAL-c339t-707f202eca004da28ed888f04aa41b4fe235ea0cba4b7bae61d698e7e323ecf13</originalsourceid><addsrcrecordid>eNo9kEtLAzEQx4MotVY_gpCD12hemwd4KaWtQsWLgrdlNptIpLtbNlmw397V1s5lmP9jDj-EMKP3jFr9QMfhhivCrNVUjRf5k87QlBVCE6b4xzmaUqE4KZSSl-gqpa8xYay0EzSxzGor2RQ9zofcNZCjw8uXNfkcYu1rXHV52MZ2aHDuvmOLc-8hN77NuAs47SCN-Zj31-giwDb5m-OeoffV8m3xRDav6-fFfEOcEDYTTXXglHsHlMoauPG1MSZQCSBZJYPnovBAXQWy0hV4xWpljddecOFdYGKGzOGv67uUeh_KXR8b6Pclo-Uvj_KfR3nicZDG6u2huhuqxten4hHA6N8dfUgOtqGH1sV0inHNmC6Y-AHOO2ia</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Automatic EMG-guided botulinum toxin treatment of spasticity</title><source>MEDLINE</source><source>Journals@Ovid Complete</source><creator>FINSTERER, J ; FUCHS, I ; MAMOLI, B</creator><creatorcontrib>FINSTERER, J ; FUCHS, I ; MAMOLI, B</creatorcontrib><description>Conventional electromyographic (EMG) guidance in botulinum toxin therapy can localize a muscle, but the amount of electrical activity is assessed only subjectively. We wanted to introduce a quantitative EMG criterion, according to which the decision for/against toxin application could be made. Turn/amplitude analysis (TAA) was applied to nine patients with severe paraspasticity (n = 5), right upper or lower limb spasticity (n = 3), or tetraspasticity (n = 1) before and after toxin administration. Muscles were selected for toxin application if both mean turns/second and mean amplitude/turn exceeded the level of 150. A mean Dysport dose of 116 mouse units (mu) (range 40-240 mu) was administered to each of the 26 muscles that met the EMG criterion. Thirty days after the injection, activities of daily living, pain, and TAA count improved in 89%, tone in 78%, and range of motion in 56% of the patients by at least 1 point on corresponding 5-point rating scales. TAA provides a useful EMG criterion for/against botulinum toxin application. Muscle selection according to this criterion leads to a significant subjective and objective toxin effect. TAA is a valuable tool to determine the benefit of single and subsequent botulinum toxin injections in the treatment of spasticity.</description><identifier>ISSN: 0362-5664</identifier><identifier>EISSN: 1537-162X</identifier><identifier>DOI: 10.1097/00002826-199706000-00002</identifier><identifier>PMID: 9197941</identifier><identifier>CODEN: CLNEDB</identifier><language>eng</language><publisher>Hagerstown, MD: Lippincott</publisher><subject>Adult ; Aged ; Anti-Dyskinesia Agents - administration & dosage ; Anti-Dyskinesia Agents - therapeutic use ; Biological and medical sciences ; Botulinum Toxins - administration & dosage ; Botulinum Toxins - therapeutic use ; Electromyography ; Female ; Humans ; Male ; Medical sciences ; Middle Aged ; Muscle ; Muscle Spasticity - drug therapy ; Muscle Spasticity - physiopathology ; Pain ; Pharmacology. Drug treatments ; Range of Motion, Articular</subject><ispartof>Clinical neuropharmacology, 1997-06, Vol.20 (3), p.195-203</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c339t-707f202eca004da28ed888f04aa41b4fe235ea0cba4b7bae61d698e7e323ecf13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=2711751$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9197941$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>FINSTERER, J</creatorcontrib><creatorcontrib>FUCHS, I</creatorcontrib><creatorcontrib>MAMOLI, B</creatorcontrib><title>Automatic EMG-guided botulinum toxin treatment of spasticity</title><title>Clinical neuropharmacology</title><addtitle>Clin Neuropharmacol</addtitle><description>Conventional electromyographic (EMG) guidance in botulinum toxin therapy can localize a muscle, but the amount of electrical activity is assessed only subjectively. We wanted to introduce a quantitative EMG criterion, according to which the decision for/against toxin application could be made. Turn/amplitude analysis (TAA) was applied to nine patients with severe paraspasticity (n = 5), right upper or lower limb spasticity (n = 3), or tetraspasticity (n = 1) before and after toxin administration. Muscles were selected for toxin application if both mean turns/second and mean amplitude/turn exceeded the level of 150. A mean Dysport dose of 116 mouse units (mu) (range 40-240 mu) was administered to each of the 26 muscles that met the EMG criterion. Thirty days after the injection, activities of daily living, pain, and TAA count improved in 89%, tone in 78%, and range of motion in 56% of the patients by at least 1 point on corresponding 5-point rating scales. TAA provides a useful EMG criterion for/against botulinum toxin application. Muscle selection according to this criterion leads to a significant subjective and objective toxin effect. TAA is a valuable tool to determine the benefit of single and subsequent botulinum toxin injections in the treatment of spasticity.</description><subject>Adult</subject><subject>Aged</subject><subject>Anti-Dyskinesia Agents - administration & dosage</subject><subject>Anti-Dyskinesia Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Botulinum Toxins - administration & dosage</subject><subject>Botulinum Toxins - therapeutic use</subject><subject>Electromyography</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Muscle</subject><subject>Muscle Spasticity - drug therapy</subject><subject>Muscle Spasticity - physiopathology</subject><subject>Pain</subject><subject>Pharmacology. Drug treatments</subject><subject>Range of Motion, Articular</subject><issn>0362-5664</issn><issn>1537-162X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1997</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kEtLAzEQx4MotVY_gpCD12hemwd4KaWtQsWLgrdlNptIpLtbNlmw397V1s5lmP9jDj-EMKP3jFr9QMfhhivCrNVUjRf5k87QlBVCE6b4xzmaUqE4KZSSl-gqpa8xYay0EzSxzGor2RQ9zofcNZCjw8uXNfkcYu1rXHV52MZ2aHDuvmOLc-8hN77NuAs47SCN-Zj31-giwDb5m-OeoffV8m3xRDav6-fFfEOcEDYTTXXglHsHlMoauPG1MSZQCSBZJYPnovBAXQWy0hV4xWpljddecOFdYGKGzOGv67uUeh_KXR8b6Pclo-Uvj_KfR3nicZDG6u2huhuqxten4hHA6N8dfUgOtqGH1sV0inHNmC6Y-AHOO2ia</recordid><startdate>19970601</startdate><enddate>19970601</enddate><creator>FINSTERER, J</creator><creator>FUCHS, I</creator><creator>MAMOLI, B</creator><general>Lippincott</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19970601</creationdate><title>Automatic EMG-guided botulinum toxin treatment of spasticity</title><author>FINSTERER, J ; FUCHS, I ; MAMOLI, B</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c339t-707f202eca004da28ed888f04aa41b4fe235ea0cba4b7bae61d698e7e323ecf13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1997</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Anti-Dyskinesia Agents - administration & dosage</topic><topic>Anti-Dyskinesia Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Botulinum Toxins - administration & dosage</topic><topic>Botulinum Toxins - therapeutic use</topic><topic>Electromyography</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Muscle</topic><topic>Muscle Spasticity - drug therapy</topic><topic>Muscle Spasticity - physiopathology</topic><topic>Pain</topic><topic>Pharmacology. Drug treatments</topic><topic>Range of Motion, Articular</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>FINSTERER, J</creatorcontrib><creatorcontrib>FUCHS, I</creatorcontrib><creatorcontrib>MAMOLI, B</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Clinical neuropharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>FINSTERER, J</au><au>FUCHS, I</au><au>MAMOLI, B</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Automatic EMG-guided botulinum toxin treatment of spasticity</atitle><jtitle>Clinical neuropharmacology</jtitle><addtitle>Clin Neuropharmacol</addtitle><date>1997-06-01</date><risdate>1997</risdate><volume>20</volume><issue>3</issue><spage>195</spage><epage>203</epage><pages>195-203</pages><issn>0362-5664</issn><eissn>1537-162X</eissn><coden>CLNEDB</coden><abstract>Conventional electromyographic (EMG) guidance in botulinum toxin therapy can localize a muscle, but the amount of electrical activity is assessed only subjectively. We wanted to introduce a quantitative EMG criterion, according to which the decision for/against toxin application could be made. Turn/amplitude analysis (TAA) was applied to nine patients with severe paraspasticity (n = 5), right upper or lower limb spasticity (n = 3), or tetraspasticity (n = 1) before and after toxin administration. Muscles were selected for toxin application if both mean turns/second and mean amplitude/turn exceeded the level of 150. A mean Dysport dose of 116 mouse units (mu) (range 40-240 mu) was administered to each of the 26 muscles that met the EMG criterion. Thirty days after the injection, activities of daily living, pain, and TAA count improved in 89%, tone in 78%, and range of motion in 56% of the patients by at least 1 point on corresponding 5-point rating scales. TAA provides a useful EMG criterion for/against botulinum toxin application. Muscle selection according to this criterion leads to a significant subjective and objective toxin effect. TAA is a valuable tool to determine the benefit of single and subsequent botulinum toxin injections in the treatment of spasticity.</abstract><cop>Hagerstown, MD</cop><pub>Lippincott</pub><pmid>9197941</pmid><doi>10.1097/00002826-199706000-00002</doi><tpages>9</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0362-5664 |
ispartof | Clinical neuropharmacology, 1997-06, Vol.20 (3), p.195-203 |
issn | 0362-5664 1537-162X |
language | eng |
recordid | cdi_crossref_primary_10_1097_00002826_199706000_00002 |
source | MEDLINE; Journals@Ovid Complete |
subjects | Adult Aged Anti-Dyskinesia Agents - administration & dosage Anti-Dyskinesia Agents - therapeutic use Biological and medical sciences Botulinum Toxins - administration & dosage Botulinum Toxins - therapeutic use Electromyography Female Humans Male Medical sciences Middle Aged Muscle Muscle Spasticity - drug therapy Muscle Spasticity - physiopathology Pain Pharmacology. Drug treatments Range of Motion, Articular |
title | Automatic EMG-guided botulinum toxin treatment of spasticity |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T00%3A54%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Automatic%20EMG-guided%20botulinum%20toxin%20treatment%20of%20spasticity&rft.jtitle=Clinical%20neuropharmacology&rft.au=FINSTERER,%20J&rft.date=1997-06-01&rft.volume=20&rft.issue=3&rft.spage=195&rft.epage=203&rft.pages=195-203&rft.issn=0362-5664&rft.eissn=1537-162X&rft.coden=CLNEDB&rft_id=info:doi/10.1097/00002826-199706000-00002&rft_dat=%3Cpubmed_cross%3E9197941%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/9197941&rfr_iscdi=true |